Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$193.33 USD
-1.05 (-0.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $192.63 -0.70 (-0.36%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
MDGL 193.33 -1.05(-0.54%)
Will MDGL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MDGL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MDGL
Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals
2 Top Biotech Buyout Candidates
MDGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
Akero (AKRO) Slumps 63% on Mixed Results From NASH Study
Other News for MDGL
Biotech Alert: Searches spiking for these stocks today
Madrigal Statement on the Passing of Dr. Stephen Harrison
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
3 Potential Biopharma Buyout Targets
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024